INTS

Intensity is a late-stage clinical-stage biotech with zero product revenue in any year shown (FY2022–FY2025) and a lead candidate, INT230-6, that has completed Phase 1/2 (IT-01) and Phase 2 (INVINCIBLE-2) work but has no FDA approval and no marketed product. Its own 10-K states the auditor issued a going-concern opinion 'as a result of recurring losses from operations and negative cash flows from operations,' and management concedes it 'will need to raise substantial additional funding or… delay, reduce or eliminate' programs. That single disclosure dominates the numbers: this is a survival-and-dilution story, not a fundamentals story.

The balance sheet buys time but not comfort. FY2025 cash of $11.9M against operating cash burn of -$9.23M implies only ~1.3 years of runway at the current pace, and the company is explicit that its 'prospects for obtaining additional financing are uncertain.' The optics look tidy — liabilities/equity of just 0.19x and equity that jumped to $11.9M (+307%) — but that equity was manufactured by a capital raise, not by the business; retained deficit is -$78.4M and ROE is -97.7%. Note also shares outstanding collapsed 83.3% to 2.54M (a reverse split), which is why diluted EPS reads -$8.56; the 'improvements' in per-share and YoY loss figures are optical, not operational.